Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): In vitro and ex vivo studies

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 6, 2012, Pages 1034-1041

  Araújo, Joana ^a   Garcia, Maria L ^a   Mallandrich, Mireia ^a   Souto, Eliana B ^b,c   Calpena, Ana C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Nanostructured lipid carrier; Permeation; Sclera; Sustained release; Triamcinolone acetonide

Indexed keywords

DIFFUSION CELLS; DRUG CONTENT; DRUG RELEASE; EX-VIVO; HEPES BUFFER; HIGH PRESSURE HOMOGENIZATION; IN-VITRO; INFLAMMATORY DISORDERS; LIPID CARRIERS; MACULAR EDEMA; NANO-SIZE; NANOSTRUCTURED LIPID CARRIERS; NEOVASCULARIZATION; OCULAR DISEASE; POSTERIOR SEGMENT; RELEASE PROFILES; RP-HPLC; SCLERA; SUSTAINED RELEASE; THERAPY STRATEGIES; TISSUE SECTIONS; TRIAMCINOLONE ACETONIDE; ZERO ORDER KINETICS;

DIALYSIS; DISEASE CONTROL; DRUG PRODUCTS; PERMEATION; TISSUE;

ACETONE;

DRUG CARRIER; LIPID; NANOCOATING; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOROID; DRUG PENETRATION; DRUG RELEASE; EX VIVO STUDY; IN VITRO STUDY; MALE; NONHUMAN; RABBIT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCLERA;

ANIMALS; DELAYED-ACTION PREPARATIONS; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; LIPOSOMES; NANOCAPSULES; NANOSTRUCTURES; PERMEABILITY; RABBITS; SCLERA; TRIAMCINOLONE ACETONIDE;

ORYCTOLAGUS CUNICULUS;

EID: 84864083659     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.10.015     Document Type: Article

References (32)

1. Jermak C.M., Dellacroce J.T., Heffez J., Peyman G.A. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007, 52:503-522.
2. Ranta V.P., Mannermaa E., Lummepuro K., Subrizi A., Laukkanen A., Antopolsky M., et al. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release 2010, 148:42-48.
3. Felt-Baeyens O., Eperon S., Mora P., Limal D., Sagodira S., Breton P., et al. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int J Pharm 2006, 322:6-12.
4. Eljarrat-Binstock E., Pe'er J., Domb A. New techniques for drug delivery to the posterior eye segment. Pharm Res 2010, 27:530-543.
5. Geroski D.H., Edelhauser H.F. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001, 52:37-48.
6. Morales M.E., Gallardo Lara V., Calpena A.C., Doménech J., Ruiz M.A. Comparative study of morphine diffusion from sustained release polymeric suspensions. J Control Release 2004, 95:75-81.
7. Araújo J., Gonzalez E., Egea M.A., Garcia M.L., Souto E.B. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 2009, 5:394-401.
8. Souto E.B., Doktorovova S., Gonzalez-Mira E., Egea M.A., Garcia M.L. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr Eye Res 2010, 35:537-552.
9. Mansoor S., Kuppermann B., Kenney M. Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res 2009, 26:770-784.
10. Müller R.H., Petersen R.D., Hommoss A., Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007, 59:522-530.
11. Müller R.H., Radtke M., Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002, 242:121-128.
12. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001, 47:165-196.
13. Hu F.Q., Jiang S.P., Du Y.Z., Yuan H., Ye Y.Q., Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm 2006, 314:83-89.
14. Puglia C., Blasi P., Rizza L., Schoubben A., Bonina F., Rossi C., et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm 2008, 357:295-304.
15. Souto E.B., Muller R.H. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 2006, 23:377-388.
16. Joshi M., Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 2008, 346:124-132.
17. Araújo J., Gonzalez-Mira E., Egea M.A., Garcia M.L., Souto E.B. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm 2010, 393:168-176.
18. Müller R.H. LJS, inventor. Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN) 1996.
19. Magenheim B., Benita S. Nanoparticle characterization: a comprehensive physicochemical approach. STP Pharma Sci 1991, 1:221-241.
20. European Medicines Agency Doc. Ref: EMEA7CHMP/EWP/192217/2009. Guideline on validation of bioanalytical methods. London 2009.
21. Olsen T.W., Edelhauser H.F., Lim J.I., Geroski D.H. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci 1995, 36:1893-1903.
22. ICH Harmonised Tripartite Guideline Validation of analytical procedures: text and methodology Q2(R1). Current Step 4 version Parent Guideline dated 27 October 1994 [complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005.
23. Gupta C., Chauhan A. Ophthalmic delivery of cyclosporine a by punctal plugs. J Control Release 2010, 150:70-76.
24. Williams A.C., Cornwell P.A., Barry B.W. On the non-Gaussian distribution of human skin permeabilities. Intl J Pharm 1992, 86:69-77.
25. Jenke D.R. Chromatographic method validation: a review of current practices and procedures. II. Guidelines for primary validation parameters. J Liq Chrom Relat Tech 1996, 19:737-757.
26. Uchizono J.A. Application of pharmacokinetics and pharmacodynamics in the design of controlled delivery systems. Design of controlled release drug delivery systems 2006, 1-39. McGraw-Hill Professional, New York. X. Li (Ed.).
27. Robinson M.R., Lee S.S., Kim H., Kim S., Lutz R.J., Galban C., et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 2006, 82:479-487.
28. Ambati J., Canakis C.S., Miller J.W., Gragoudas E.S., Edwards A., Weissgold D.J., et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000, 41:1181-1185.
29. Williams A.C. Transdermal and topical drug delivery 2003, 27-49. Pharmaceutical Press, London.
30. Puglia C., Filosa R., Peduto A., de Caprariis P., Rizza L., Bonina F., et al. Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS PharmSciTech 2006, 7:E61-E69.
31. Jain S.K., Chourasia M.K., Masuriha R., Soni V., Jain A., Jain N.K., et al. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv 2005, 12:207-215.
32. Mei Z., Chen H., Weng T., Yang Y., Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 2003, 56:189-196.